BDNF Interactions: What the Literature Reports on Alcohol, Caffeine, Food and Other Compounds

What an "interaction" means in BDNF research

Brain-derived neurotrophic factor (BDNF) is an endogenous protein, not an administered compound, so the word "interaction" carries a different meaning here than it does for two drugs taken together. In the published literature, questions about BDNF and alcohol, caffeine, food or supplements are usually addressed in one of three ways: an exposure is applied to an animal or human and BDNF-related signalling is measured; BDNF genotype or circulating BDNF is measured and correlated with behaviour toward a substance or stimulus; or a compound is given to a group and serum BDNF is sampled. Very few studies were designed as true co-administration experiments, and this page separates what was measured from what is merely inferred.

This page is for educational purposes only and is not medical advice; consult a licensed physician about anything relating to health, medication or supplements. Nothing below describes a protocol, and no combination is characterised as appropriate or inappropriate — only as studied or unstudied. For background on the molecule itself, see the hub page at /learn/bdnf/.

Alcohol and BDNF: What Studies Report

Binge-pattern exposure and neuroimmune changes

Rodent work has repeatedly used binge-style dosing schedules rather than chronic low-level intake. A 2020 study in Frontiers in Neuroanatomy examined binge-like alcohol exposure in adolescent and adult male rats and reported microglial dystrophy in the exposed animals, with the authors framing morphological change in these immune cells as a consequence of the exposure pattern (PMID 32903737). Microglia are a source and regulator of neurotrophic signalling, which is why alcohol–neuroimmune papers are frequently cited in BDNF discussions even when BDNF itself was not the primary readout of that particular study (PMID 32903737).

Restoring pERK–BDNF signalling after alcohol exposure

A 2024 report in the Journal of Molecular Neuroscience tested the small molecule BCI in an alcohol-exposure model and reported improvements in alcohol-induced cognitive and emotional impairments, which the researchers attributed to restoration of phosphorylated ERK and BDNF signalling (PMID 38890235). This is one of the clearest examples in the verified set of alcohol being treated as a BDNF-suppressing exposure that another compound was then used to counteract, rather than as a substance whose combination with BDNF was evaluated (PMID 38890235).

Withdrawal, depression-like behaviour and stress overlap

Withdrawal, not intoxication, is the phase most often studied. A 2025 paper in Frontiers in Pharmacology administered fenofibrate during withdrawal in male rats and reported reversal of symptoms of ethanol-induced depression (PMID 40860877). A separate 2025 Frontiers in Pharmacology study reported that alcohol exposure exacerbated PTSD-like behaviours in an animal model and examined the cAMP–PKA pathway as the regulatory mechanism involved (PMID 40453656). Mechanistic reasoning, not a finding: cAMP–PKA signalling sits upstream of CREB-dependent transcription, which is one of the canonical routes to BDNF expression, and this is the reasoning researchers use when connecting that pathway work to neurotrophin outcomes — the study cited examined the pathway and behaviour, and readers should not treat the connection as a measured BDNF result (PMID 40453656).

Across these four reports, the models were male rodents, the exposures were experimenter-controlled, and the endpoints were behaviour, cell morphology and signalling proteins (PMID 32903737, PMID 40860877). None of them evaluated human drinking patterns alongside administered BDNF or BDNF-targeting agents.

Caffeine and BDNF: what the verified literature does and does not cover

This is the clearest gap on the page. The caffeine papers in the verified set were not designed as caffeine–BDNF interaction experiments, and stating otherwise would misrepresent them. A 2024 systematic review in the Journal of Translational Medicine synthesised genetic susceptibility to caffeine intake and metabolism, describing how inherited variation shapes how much caffeine people consume and how quickly they process it (PMID 39438936). A 2021 Frontiers in Pharmacology study reported that caffeine protected against retinal inflammation, with the stated focus on inflammatory signalling in ocular tissue rather than on a neurotrophin co-administration design (PMID 35069225). A 2022 paper in Current Drug Delivery developed a nasal caffeine thermo-sensitive in situ gel and reported enhanced cognition after sleep deprivation, an outcome measured behaviourally in the formulation's test model (PMID 35579146).

Plain statement of the gap: no study in this page's verified set administered caffeine and measured BDNF, and no study evaluated caffeine alongside a BDNF-targeting agent. Mechanistic reasoning, labelled as such: investigators who speculate about caffeine and neurotrophins typically reason from adenosine receptor antagonism to downstream cAMP and CREB activity, the same transcriptional route invoked in the alcohol–PTSD pathway work (PMID 40453656). That is a hypothesis about plausibility, not a measured interaction, and the caffeine metabolism review is a reminder that between-person genetic variability would complicate any such measurement (PMID 39438936).

Food, feeding behaviour and BDNF

Food cues and craving in humans

The most direct human food-related evidence in this set comes from a 2021 study in European Archives of Psychiatry and Clinical Neuroscience, which reported that BDNF influenced neural cue-reactivity to food stimuli and food craving in participants with obesity (PMID 33367955). The design linked BDNF status to brain responses evoked by food images and to self-reported craving rather than to weight change, so the reported relationship concerns reactivity and subjective craving (PMID 33367955).

Hypothalamic circuits, reward seeking and jaw movement

A 2021 paper in Progress in Neurobiology reported that LSD1–BDNF activity in the lateral hypothalamus–medial forebrain bundle area was essential for reward-seeking behaviour, placing BDNF inside a circuit that governs motivated approach to rewards including food (PMID 33798614). Separately, a 2024 Nature study mapped a subcortical feeding circuit linking an interoceptive node to jaw movement, describing how internal-state signals are translated into the mechanics of eating (PMID 39443799). The Nature circuit paper was a feeding-neuroanatomy study and not a BDNF measurement study, and it is included here only to show the circuitry level at which feeding questions are now addressed (PMID 39443799).

Fasting and meal timing

Plain statement of the gap: the verified papers behind this page include no fasting trial, no ketogenic-diet trial and no meal-timing trial with BDNF endpoints, so nothing here supports any claim about fasting and BDNF in either direction. What the set does support is that BDNF sits within hypothalamic reward and feeding circuitry (PMID 33798614) and tracks with food-cue reactivity in humans with obesity (PMID 33367955) — which is the reason researchers keep testing energy-state manipulations, not evidence that those manipulations have been tested here.

Other compounds studied alongside BDNF

Iron plus a bioavailable curcumin supplement

The clearest human co-administration result in this set is a 2020 study in Antioxidants, which reported that co-administration of iron and a bioavailable curcumin supplement increased serum BDNF levels in healthy adults (PMID 32707771). That study measured a circulating blood marker in healthy volunteers, which is a different endpoint from brain-tissue BDNF protein or activity-dependent release, and the researchers reported the serum change rather than any cognitive or clinical outcome (PMID 32707771).

mTOR inhibition and memory processes

Because BDNF–TrkB signalling converges on mTOR-dependent protein synthesis, pharmacological mTOR inhibition is a common experimental probe. A 2021 study in Learning & Memory reported that mTOR inhibition impaired extinction memory reconsolidation (PMID 33323495). The study addressed a downstream translational pathway rather than BDNF levels directly, and it is cited in interaction discussions because it illustrates how blocking a shared node changes a behavioural outcome (PMID 33323495).

Summary table of what was actually examined

Interaction-Related Adverse Events: What Studies Report

The negative outcomes described in this literature belong to the exposures themselves, mostly alcohol, and were observed in controlled animal experiments. The 2020 rodent study reported microglial dystrophy following binge-like alcohol exposure in both adolescent and adult male rats (PMID 32903737). The 2025 withdrawal study characterised depression-like symptoms following ethanol exposure in male rats as the condition its treatment arm was intended to reverse (PMID 40860877). The 2025 cAMP–PKA study reported that alcohol exposure exacerbated PTSD-like behaviours (PMID 40453656), and the 2024 BCI study described alcohol-induced cognitive and emotional impairments as its baseline deficit (PMID 38890235). No tolerability data for combining BDNF-related agents with caffeine, food-state manipulations or supplements appear in this verified set.

How to read this evidence

• Species and sex matter: the alcohol findings summarised above came from male rodents under experimenter-controlled exposure (PMID 32903737, PMID 40860877).
• Serum is not brain: the human supplement result was a circulating BDNF measurement in healthy adults (PMID 32707771).
• Association is not manipulation: the food-cue work related BDNF to reactivity and craving rather than altering BDNF and observing an outcome (PMID 33367955).
• Pathway probes are indirect: mTOR inhibition changed extinction memory reconsolidation without being a BDNF-dosing experiment (PMID 33323495).

References

• Microglia Dystrophy Following Binge-Like Alcohol Exposure in Adolescent and Adult Male Rats (Frontiers in Neuroanatomy, 2020)
• BCI Improves Alcohol-Induced Cognitive and Emotional Impairments by Restoring pERK-BDNF (Journal of Molecular Neuroscience, 2024)
• Fenofibrate treatment during withdrawal reverses symptoms of ethanol-induced depression in male rats (Frontiers in Pharmacology, 2025)
• The regulation and mechanism of the cAMP-PKA pathway on PTSD-like behaviors exacerbated by alcohol exposure (Frontiers in Pharmacology, 2025)
• Genetic susceptibility to caffeine intake and metabolism: a systematic review (Journal of Translational Medicine, 2024)
• Caffeine Protects Against Retinal Inflammation (Frontiers in Pharmacology, 2021)
• Nasal Caffeine Thermo-Sensitive In Situ Gel for Enhanced Cognition after Sleep-Deprivation (Current Drug Delivery, 2022)
• BDNF influences neural cue-reactivity to food stimuli and food craving in obesity (European Archives of Psychiatry and Clinical Neuroscience, 2021)
• LSD1-BDNF activity in lateral hypothalamus-medial forebrain bundle area is essential for reward seeking behavior (Progress in Neurobiology, 2021)
• A subcortical feeding circuit linking an interoceptive node to jaw movement (Nature, 2024)
• Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults (Antioxidants, 2020)
• mTOR inhibition impairs extinction memory reconsolidation (Learning & Memory, 2021)